Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and ConcertAI, a leading oncology real-world evidence data and AI SaaS technology company, today announced a collaboration agreement that allows biopharmaceutical companies to access the first multi-modal real-world data (RWD) that integrates comprehensive patient electronic medical record (EMR) data with both genomic and epigenomic tumor profiling information across the continuum of cancer care.

Lymphoma, also known as malignant lymphoma, is a general term for a group of malignant tumors originating from the lymphopoietic system. It is one of the most common tumors in China. In 2020, there were 544,352 new cases of non-Hodgkin lymphoma (NHL) worldwide, ranking 13th among all new cases of malignancies.

Gastric cancer is a common gastrointestinal carcinoid tumor, with the sixth highest incidence and second highest mortality rate among tumors.

The U.S. Preventive Services Task Force (USPSTF) recommends four types of screening for cancers: lung cancer, colorectal cancer, breast cancer, and cervical cancer.

Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced updates to its agreement with Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies.

According to the statistics published on the website of the NMPA, in 2020, NMPA approved eight models, one is for fluorescent PCR data analysis, one is for chip data analysis, five are for sequencing data analysis, and one is for interpretation of tumor and genetic disease gene detection results.

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the launch of the first clinically approved, highly-sensitive in-situ hybridisation (ISH) test, the VENTANA® Kappa and Lambda Dual ISH mRNA Probe Cocktail assay, in countries accepting the CE Mark. The test is designed to help pathologists differentiate a B-cell malignancy from a normal, reactive response to an infection.

The Association for Molecular Pathology on Thursday published a new set of evidence-based recommendations for the analytical validation and reporting of tumor mutational burden (TMB) testing.

In the First Catalogue of Rare Diseases, which was jointly developed by the National Health Commission of the PRC and five other departments in 2018, there is a rare disease called IgG4-Related Disease (IgG4-RD).

The American Society of Clinical Oncology on Friday released guidelines to help guide use of multigene germline genetic testing panels for cancer patients.